Aciex Therapeutics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Aciex Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 8 completed upper quartile by trial count

Aciex Therapeutics: 8 sponsored US clinical trials, none currently recruiting.

Aciex Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 4 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Allergic Conjunctivitis, with 1 trials.

Upper-quartile sponsor footprint

Aciex Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 1

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

NCT02173249
COMPLETED Phase 3

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

NCT02132169
COMPLETED Phase 3

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
COMPLETED Phase 3

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01685242
COMPLETED Phase 3

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

NCT01551056
COMPLETED Phase 1

A Comparison of the Safety and Comfort of AC-170

NCT01495338
COMPLETED Phase 2

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

NCT01332188
COMPLETED Phase 2

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

NCT01134328

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 4

Therapeutic Areas

Allergic Conjunctivitis 1
Healthy 1

How the Aciex Therapeutics archive is shaped

8 indexed studies, none listed as recruiting (0% open); 8 completed (100%).

Phase mix: 4 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Allergic Conjunctivitis (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Aciex Therapeutics: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Aciex Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Aciex TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Aciex Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aciex Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aciex Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Aciex Therapeutics or any single study.

  • None of Aciex Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Allergic Conjunctivitis is the condition Aciex Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Allergic Conjunctivitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aciex Therapeutics pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.